The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Mucormycosis-Global Market Insights and Sales Trends 2024
Synopsis
Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the Mucor, Rhizopus, Absidia, and Cunninghamella genera are most often implicated. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immunocompromised individuals.
The global Mucormycosis market size is expected to reach US$ 626.7 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Mucormycosis in various end use industries. The expanding demands from the Hospitals & Clinics, Medical Institutes, Research Organization and Others, are propelling Mucormycosis market. Computed Tomography (CT), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Magnetic resonance imaging (MRI) segment is estimated at % CAGR for the next seven-year period.
If mucormycosis is suspected, amphotericin B therapy should be immediately administered due to the rapid spread and high mortality rate of the disease. Amphotericin B is usually administered for an additional 4–6 weeks after initial therapy begins to ensure eradication of the infection. After administration of either amphotericin B or posaconazole, surgical removal of the "fungus ball" is indicated. The disease must be monitored carefully for any signs of reemergence.
Report Objectives
This report provides market insight on the different segments, by players, by Diagnosis, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Mucormycosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Mucormycosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Mucormycosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Mucormycosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Mucormycosis covered in this report include Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, Merck, Roche, Bristol Myers Squibb and Pfizer, etc.
The global Mucormycosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
Merck
Roche
Bristol Myers Squibb
Pfizer
Global Mucormycosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Mucormycosis market, Segment by Diagnosis:
Computed Tomography (CT)
Magnetic resonance imaging (MRI)
Tissue Biopsy
Others
Global Mucormycosis market, by Application
Hospitals & Clinics
Medical Institutes
Research Organization
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Diagnosis, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Mucormycosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the Mucor, Rhizopus, Absidia, and Cunninghamella genera are most often implicated. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immunocompromised individuals.
The global Mucormycosis market size is expected to reach US$ 626.7 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Mucormycosis in various end use industries. The expanding demands from the Hospitals & Clinics, Medical Institutes, Research Organization and Others, are propelling Mucormycosis market. Computed Tomography (CT), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Magnetic resonance imaging (MRI) segment is estimated at % CAGR for the next seven-year period.
If mucormycosis is suspected, amphotericin B therapy should be immediately administered due to the rapid spread and high mortality rate of the disease. Amphotericin B is usually administered for an additional 4–6 weeks after initial therapy begins to ensure eradication of the infection. After administration of either amphotericin B or posaconazole, surgical removal of the "fungus ball" is indicated. The disease must be monitored carefully for any signs of reemergence.
Report Objectives
This report provides market insight on the different segments, by players, by Diagnosis, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Mucormycosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Mucormycosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Mucormycosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Mucormycosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Mucormycosis covered in this report include Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, Merck, Roche, Bristol Myers Squibb and Pfizer, etc.
The global Mucormycosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
Merck
Roche
Bristol Myers Squibb
Pfizer
Global Mucormycosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Mucormycosis market, Segment by Diagnosis:
Computed Tomography (CT)
Magnetic resonance imaging (MRI)
Tissue Biopsy
Others
Global Mucormycosis market, by Application
Hospitals & Clinics
Medical Institutes
Research Organization
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Diagnosis, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Mucormycosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Mucormycosis
1.1 Mucormycosis Market Overview
1.1.1 Mucormycosis Product Scope
1.1.2 Mucormycosis Market Status and Outlook
1.2 Global Mucormycosis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Mucormycosis Market Size by Region (2018-2029)
1.4 Global Mucormycosis Historic Market Size by Region (2018-2023)
1.5 Global Mucormycosis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Mucormycosis Market Size (2018-2029)
1.6.1 North America Mucormycosis Market Size (2018-2029)
1.6.2 Europe Mucormycosis Market Size (2018-2029)
1.6.3 Asia-Pacific Mucormycosis Market Size (2018-2029)
1.6.4 Latin America Mucormycosis Market Size (2018-2029)
1.6.5 Middle East & Africa Mucormycosis Market Size (2018-2029)
2 Mucormycosis Market by Diagnosis
2.1 Introduction
2.1.1 Computed Tomography (CT)
2.1.2 Magnetic resonance imaging (MRI)
2.1.3 Tissue Biopsy
2.1.4 Others
2.2 Global Mucormycosis Market Size by Diagnosis: 2018 VS 2022 VS 2029
2.2.1 Global Mucormycosis Historic Market Size by Diagnosis (2018-2023)
2.2.2 Global Mucormycosis Forecasted Market Size by Diagnosis (2024-2029)
2.3 Key Regions Market Size by Diagnosis
2.3.1 North America Mucormycosis Revenue Breakdown by Diagnosis (2018-2029)
2.3.2 Europe Mucormycosis Revenue Breakdown by Diagnosis (2018-2029)
2.3.3 Asia-Pacific Mucormycosis Revenue Breakdown by Diagnosis (2018-2029)
2.3.4 Latin America Mucormycosis Revenue Breakdown by Diagnosis (2018-2029)
2.3.5 Middle East and Africa Mucormycosis Revenue Breakdown by Diagnosis (2018-2029)
3 Mucormycosis Market Overview by Application
3.1 Introduction
3.1.1 Hospitals & Clinics
3.1.2 Medical Institutes
3.1.3 Research Organization
3.1.4 Others
3.2 Global Mucormycosis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Mucormycosis Historic Market Size by Application (2018-2023)
3.2.2 Global Mucormycosis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Mucormycosis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Mucormycosis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Mucormycosis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Mucormycosis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Mucormycosis Revenue Breakdown by Application (2018-2029)
4 Mucormycosis Competition Analysis by Players
4.1 Global Mucormycosis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mucormycosis as of 2022)
4.3 Date of Key Players Enter into Mucormycosis Market
4.4 Global Top Players Mucormycosis Headquarters and Area Served
4.5 Key Players Mucormycosis Product Solution and Service
4.6 Competitive Status
4.6.1 Mucormycosis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Mucormycosis Products, Services and Solutions
5.1.4 Abbott Laboratories Mucormycosis Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 Biocon
5.2.1 Biocon Profile
5.2.2 Biocon Main Business
5.2.3 Biocon Mucormycosis Products, Services and Solutions
5.2.4 Biocon Mucormycosis Revenue (US$ Million) & (2018-2023)
5.2.5 Biocon Recent Developments
5.3 Cadila Pharmaceuticals
5.3.1 Cadila Pharmaceuticals Profile
5.3.2 Cadila Pharmaceuticals Main Business
5.3.3 Cadila Pharmaceuticals Mucormycosis Products, Services and Solutions
5.3.4 Cadila Pharmaceuticals Mucormycosis Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Mucormycosis Products, Services and Solutions
5.4.4 Novartis Mucormycosis Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Mucormycosis Products, Services and Solutions
5.5.4 Merck Mucormycosis Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Roche
5.6.1 Roche Profile
5.6.2 Roche Main Business
5.6.3 Roche Mucormycosis Products, Services and Solutions
5.6.4 Roche Mucormycosis Revenue (US$ Million) & (2018-2023)
5.6.5 Roche Recent Developments
5.7 Bristol Myers Squibb
5.7.1 Bristol Myers Squibb Profile
5.7.2 Bristol Myers Squibb Main Business
5.7.3 Bristol Myers Squibb Mucormycosis Products, Services and Solutions
5.7.4 Bristol Myers Squibb Mucormycosis Revenue (US$ Million) & (2018-2023)
5.7.5 Bristol Myers Squibb Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Mucormycosis Products, Services and Solutions
5.8.4 Pfizer Mucormycosis Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
6 North America
6.1 North America Mucormycosis Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Mucormycosis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Mucormycosis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Mucormycosis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Mucormycosis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Mucormycosis Market Dynamics
11.1 Mucormycosis Industry Trends
11.2 Mucormycosis Market Drivers
11.3 Mucormycosis Market Challenges
11.4 Mucormycosis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
